Introduction
============

Hepatocellular carcinoma (HC) is a major threat to human health. It is the fifth most common malignancy and caused more than 600,000 deaths every year.[@b1-ott-11-8835]--[@b3-ott-11-8835] Over the past 20 years, the number of HC-related deaths has increased by 62%.[@b4-ott-11-8835] China is a high-risk area for HC and accounts for more than half of the HC cases worldwide.[@b4-ott-11-8835],[@b5-ott-11-8835] Despite the development of diagnostic methods, early detection of HC is still difficult.[@b2-ott-11-8835] In most patients, HC progressed to the intermediate and advanced stage, and the 5-year survival rate was \<17% at this stage.[@b1-ott-11-8835] Therefore, only a small proportion of early-stage HC patients are suitable for radical treatment.

Transcatheter hepatic arterial chemoembolization (TACE) is the current standard locoregional treatment for advanced HC.[@b2-ott-11-8835],[@b6-ott-11-8835] Several studies reported that TACE significantly increased the survival time in HC patients compared to supportive treatments.[@b7-ott-11-8835],[@b8-ott-11-8835] However, TACE also has its own limitations, as it can further influence the liver functions and damage the hepatic arterial system of patients.[@b2-ott-11-8835],[@b9-ott-11-8835] In addition, its clinical application was also limited by drug resistance and toxic side effects.[@b1-ott-11-8835] In view of these limitations of TACE therapy for HC, complementary and alternative medicine has been increasingly used for the treatment of advanced HC.

In recent years, traditional Chinese medicine has become an important source for novel chemotherapeutic agents and was considered as a powerful method for the cancer treatment.[@b4-ott-11-8835],[@b10-ott-11-8835]--[@b12-ott-11-8835] Cinobufotalin, a cardiotonic steroid or bufadienolide, is extracted from the skin secretions of the traditional Chinese medicinal giant toads.[@b12-ott-11-8835]--[@b15-ott-11-8835] Many studies have shown that cinobufotalin has anti-tumor activity and can enhance the treatment effect of chemotherapeutics for malignancies.[@b12-ott-11-8835],[@b15-ott-11-8835],[@b16-ott-11-8835] It can inhibit the growth of vascular endothelial cells by inhibiting the expression of vascular endothelial growth factor and EGF receptor and then inhibit the growth and metastasis of the tumor.[@b17-ott-11-8835] In addition, it can also induce tumor cells apoptosis through decreasing ROS production and by destroying the structure of DNA in cancer cells.[@b14-ott-11-8835],[@b16-ott-11-8835]

Up to now, several clinic trials have been conducted to evaluate the therapeutic effects between TACE and TACE+cinobufotalin injection in advanced HC patients.[@b18-ott-11-8835]--[@b44-ott-11-8835] Despite the wide use of cinobufotalin injection in HC treatment for many years, its clinical efficacy was still not well established and recognized. Therefore, we conducted a meta-analysis to investigate the treatment effect and safety of cinobufotalin injection adjuvant therapy combined with TACE in comparison with TACE alone for end-stage HC, to provide scientific reference for the design of future clinical trials.

Materials and methods
=====================

Search strategy and selection criteria
--------------------------------------

Original articles published after 2000 were searched across eight databases, including Web of Science, Cochrane Library, PubMed, Embase, Chinese Medical Citation Index (CMCI), China National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP), and Wanfang database, with key terms "huachansu" or "cinobufotalin" "cinobufagin" or "cinobufacini" combined with "hepatocellular carcinoma" or "liver cancer". No language limits were applied. The initial search was performed in May 2018 and updated in July 2018.

Selection criteria of this study are as follows: 1) controlled trials concerning advanced HC patients; 2) literatures comparing the clinical outcomes of TACE plus cinobufotalin injection adjuvant therapy (experimental group) with TACE treatments alone (control group); and 3) articles involving more than 30 HC patients. Exclusion criteria of this study are as follows: 1) non-contrast articles, case studies, and review papers and 2) patients with mixed malignancies.

Data extraction and quality assessment
--------------------------------------

Data were extracted by two reviewers (Na Guo and Yanyan Miao) independently; disagreements were adjudicated by the third investigator (Mingzhong Sun). The extracted characteristics were summarized as follows: 1) first author's names; 2) years of publication; 3) study locations; 4) tumor stages; 5) number of cases; 6) patient ages; 7) study parameter types; 8) therapeutic regimens; 9) enrollment period and expected survival time of patients; 10) application sequence of cinobufotalin injection; and 11) manufacturer of cinobufotalin injection. The included trial's quality was evaluated according to the Cochrane Handbook.[@b45-ott-11-8835]

Outcome definition
------------------

Clinical outcomes include therapeutic effect and adverse events. Therapeutic effect was assessed in terms of the overall survival (OS) rates, complete response (CR) rates, partial response (PR) rates, stable disease (SD) rates, progressive disease (PD) rates, overall response rate (ORR; ORR=CR rate+PR rate), disease control rate (DCR; DCR=CR rate+PR rate+SD rate), and quality of life improved rate (QIR). The immune function indicators (CD3^+^, CD4^+^, and natural killer (NK) cells percentage and CD4^+^/CD8^+^ ratio) and liver function indexes including total bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and serum albumin (ALB) of HC patients were determined and compared between the two groups. Moreover, adverse events including leukopenia, thrombocytopenia, nausea and vomiting, fever, hepatotoxicity, and myelosuppression were also taken for assessment.

Statistical analyses
--------------------

The analyses were performed using Review Manager 5.3 and Stata 12.0. Between-study heterogeneity was assessed using the chi-squared statistic and quantified by *I*^2^.*I*^2^,50% indicated that the studies were homogenous.[@b46-ott-11-8835] A fixed effects model was conducted when the heterogeneity did not exist; otherwise, a random effects model was performed. OR was the principal measurement for therapeutic effects and is presented with a 95% CI. We further investigated potential sources of between-study heterogeneity by subgroup analyses based on the some baseline variables (study design and sample sizes). Publication bias was assessed visually by funnel plots and quantified in Egger's test and Begg's regression test.[@b47-ott-11-8835],[@b48-ott-11-8835] When publication bias existed, trim-and-fill method was applied to adjust the pooled estimates of potentially unpublished studies.

Results
=======

Search results
--------------

A total of 1,291 articles were identified with the initial retrieve. 717 papers were excluded due to duplication. After title and abstract review, 468 articles were further excluded because they did not include clinical trials (n=344), were reviews or meta-analysis (n=7), were unrelated studies (n=104), or were case reports (n=13), leaving 106 studies as potentially relevant. After detailed assessment of full texts, articles without the control group (n=15), patients not treated by cinobufotalin injection (n=24) or TACE (n=19), studies with insufficient data (n=7), and studies published before 2000 (n=14) were excluded. Finally, 27 trials[@b19-ott-11-8835]--[@b37-ott-11-8835] involving 2,079 advanced HC patients were included in this analysis ([Figure 1](#f1-ott-11-8835){ref-type="fig"}).

Patients' characteristics
-------------------------

After selection, all studies were carried out in the hospitals in China since 2000. In total, 1,045 advanced HC patients were treated by TACE in combination with cinobufotalin injection adjuvant therapy, while 1,034 patients were treated by TACE alone. Among all included studies, cinobufotalin injection and TACE were used simultaneously in the 16 trials,[@b19-ott-11-8835]--[@b21-ott-11-8835],[@b23-ott-11-8835],[@b24-ott-11-8835],[@b26-ott-11-8835],[@b27-ott-11-8835],[@b29-ott-11-8835]--[@b31-ott-11-8835],[@b34-ott-11-8835],[@b37-ott-11-8835]--[@b40-ott-11-8835],[@b42-ott-11-8835] whereas cinobufotalin injection was used after TACE in nine articles[@b18-ott-11-8835],[@b22-ott-11-8835],[@b25-ott-11-8835],[@b28-ott-11-8835],[@b32-ott-11-8835],[@b33-ott-11-8835],[@b35-ott-11-8835],[@b36-ott-11-8835],[@b44-ott-11-8835] and was used before TACE in two studies.[@b41-ott-11-8835],[@b43-ott-11-8835] Detailed information of the studies involved and HC patients is shown in [Tables 1](#t1-ott-11-8835){ref-type="table"}, [2](#t2-ott-11-8835){ref-type="table"}, and S1.

Quality assessment
------------------

The evaluation of bias risk is presented in [Figure 2](#f2-ott-11-8835){ref-type="fig"}. Twenty-five studies had low risk and the other two studies did not have a clear description of randomization process. All included trials did not provide clear description of performance and detection risks. One study was regarded as a high risk due to the absence of follow-up, and 20 trials were considered as unclear risk owing to selective reporting.

Therapeutic efficacy assessments
--------------------------------

As shown in [Figures 3](#f3-ott-11-8835){ref-type="fig"} and [4](#f4-ott-11-8835){ref-type="fig"} and [Table 3](#t3-ott-11-8835){ref-type="table"}, the analysis results showed that patients underwent combined therapy had significantly improved 1-, 1.5-, 2-, and 3-year OS (1-year OS, OR=2.84, 95% CI=2.20--3.67, *P*\<0.00001; 1.5-year OS, OR=3.57, 95% CI=1.92--6.66, *P*\<0.0001; 2-year OS, OR=3.17, 95% CI=2.36--4.25, *P*\<0.00001; 3-year OS, OR=2.88, 95% CI=1.82--4.57, *P*\<0.00001), CR rate (OR=1.73, 95% CI=1.04--2.87, *P*=0.03), PR rate (OR=1.61, 95% CI=1.31--1.97, *P*\<0.00001), ORR (OR=1.86, 95% CI=1.54--2.24, *P*\<0.00001), and DCR (OR=2.05, 95% CI=1.59--2.64, *P*\<0.00001) and significantly decreased PD rate (OR=0.46, 95% CI=0.35--0.59, *P*\<0.00001), whereas the 0.5-year OS and SD rate (0.5-year OS, OR=1.40, 95% CI=0.97--2.01, *P*=0.07; SD rate, OR=0.88, 95% CI=0.72--1.09, *P*=0.25) did not show significant difference from patients who received TACE alone.

Quality of life assessment
--------------------------

Thirteen studies[@b18-ott-11-8835]--[@b22-ott-11-8835],[@b25-ott-11-8835],[@b26-ott-11-8835],[@b28-ott-11-8835],[@b31-ott-11-8835],[@b34-ott-11-8835],[@b35-ott-11-8835],[@b43-ott-11-8835],[@b44-ott-11-8835] assessed the quality of life of advanced HC patients between the TACE+cinobufotalin injection and TACE alone groups. Results showed that quality of life of patients in the combined group was significantly better than that of the control group, indicated by significantly improved QIR ([Figure 5](#f5-ott-11-8835){ref-type="fig"}; OR=3.45, 95% CI=2.52--4.72, *P*\<0.00001).

Liver function evaluation
-------------------------

Five clinical trials[@b24-ott-11-8835],[@b26-ott-11-8835],[@b32-ott-11-8835],[@b42-ott-11-8835],[@b44-ott-11-8835] evaluated the liver function of advanced HC patients between the two groups. As shown in [Figure 6](#f6-ott-11-8835){ref-type="fig"}, the liver function of HC patients who received combined therapy was significantly improved compared with TACE alone, indicated by obviously reduced TBIL, AST, and ALT (TBIL, OR=−9.21, 95% CI=−15.14 to −3.10, *P*=0.003; ALT, OR=−30.76, 95% CI=−41.65 to −19.88, *P*\<0.00001; AST, OR=−30.66, 95% CI=−42.36 to −18.97, *P*\<0.00001; ALB, OR=2.46, 95% CI=−2.75 to 7.67, *P*=0.35).

Immune function evaluation
--------------------------

The immune status of patients was examined between TACE and TACE+cinobufotalin injection group in five controlled studies.[@b23-ott-11-8835],[@b26-ott-11-8835],[@b29-ott-11-8835],[@b36-ott-11-8835],[@b43-ott-11-8835] Compared with TACE alone, the percentages of CD3^+^, CD4^+^, and NK cells, and CD4^+^/CD8^+^ ratio in the combined treatment group were significantly increased ([Figure 7](#f7-ott-11-8835){ref-type="fig"}; CD3^+^, OR=9.05, 95% CI=3.62--14.49, *P*=0.001; CD4^+^, OR=7.42, 95% CI=3.20--11.63, *P*=0.0006; NK, OR=10.00, 95% CI=2.08--17.92, *P*=0.01; CD4^+^/CD8^+^, OR=0.33, 95% CI=0.03--0.62, *P*=0.03).

Adverse events assessment
-------------------------

Safety of cinobufotalin injection-mediated therapy was evaluated in eight studies.[@b20-ott-11-8835]--[@b22-ott-11-8835],[@b28-ott-11-8835],[@b30-ott-11-8835],[@b32-ott-11-8835],[@b35-ott-11-8835],[@b38-ott-11-8835] As shown in [Figure 8](#f8-ott-11-8835){ref-type="fig"}, no serious adverse events were reported during cinobufotalin injection-mediated therapy. The group that received TACE plus cinobufotalin injection had lower rates of myelosuppression (OR=0.29, 95% CI=0.15--0.57, *P*=0.0003), whereas analysis on other adverse events did not show significant difference (leukopenia, OR=2.74, 95% CI=0.25--30.43, *P*=0.41; thrombocytopenia, OR=1.08, 95% CI=0.46--2.52, *P*=0.86; nausea and vomiting, OR=0.57, 95% CI=0.21--1.57, *P*=0.28; fever, OR=1.23, 95% CI=0.16--9.78, *P*=0.84; hepatotoxicity, OR=0.83, 95% CI=0.22--3.13, *P*=0.79).

Publication bias
----------------

Publication bias was assessed visually by funnel plots and quantified in Egger's test and Begg's regression test. As shown in [Figures 9](#f9-ott-11-8835){ref-type="fig"} and [10](#f10-ott-11-8835){ref-type="fig"} and [Table 4](#t4-ott-11-8835){ref-type="table"}, no significant publication bias for OS rate, CR rate, PR rate, SD rate, PD rate, and QIR was observed in these analyses, which confirmed the reliability of our primary conclusions.

Sensitivity analysis
--------------------

We conducted subgroup analysis to explore the source of heterogeneity in OS rate, ORR, DCR, and QIR with respect to the study design and sample sizes of involved studies. As shown in [Table 5](#t5-ott-11-8835){ref-type="table"}, our analysis results showed that no significant difference was found between different study designs and sample sizes of studies in most of the primary indicators except 0.5-year OS.

Discussion
==========

In view of the limitations such as drug resistance and toxic side effects of the current chemotherapy for malignancies, more and more physicians are trying to find more adjunctive or auxiliary therapies to improve patients' survival time or quality of life and to reduce side effects caused by chemotherapy. Traditional Chinese medicine has been utilized as an adjuvant method to treat HC for a long time. Several studies have been reported that the addition of cinobufotalin injection could be beneficial to patients with advanced HC. Even though there were statistical analyses of published clinical trials, the exact therapeutic effects were still not systematically evaluated because of small sample sizes and different applied protocols in different studies. In this analysis, we conducted a wide range of online search according to the strict inclusion and exclusion criteria, by which to provide clear and systematical conclusion.

Our meta-analysis revealed that TACE combined with cinobufotalin injection adjuvant therapy is associated with a favorable efficacy compared to HC patients treated by TACE alone. Compared to patients treated by TACE alone, patients treated with combined therapy showed markedly increased 1- to 3-year OS, CR rate, PR rate, ORR, DCR, and QIR (*P*\<0.05). Moreover, after TACE and cinobufotalin injection combined treatment, the liver function of HC patients was obviously improved, indicated by increased ALB and decreased TBIL, ALT, and AST, although changes in ALB did not show statistical significance. These results indicated that intravenous infusion of cinobufotalin injection could increase the curative effect of TACE.

The immunosuppressed status of cancer patients has been reported previously.[@b47-ott-11-8835] Therefore, immune system reconstruction is one of the critical factors to effectively treat malignancies.[@b47-ott-11-8835] Many studies reported that cinobufotalin injection can enhance the ability of body's immunity and resistance to tumors by increasing the IL-2 and interferon (IFN)-γ secretion of T cells and the activities of NK cells and by promoting the maturation of dendritic cells and upregulating the expression of costimulatory molecules in dendritic cells. Our analysis showed significantly increased percentages of CD3^+^, CD4^+^, NK, and CD3^+^CD56^+^ T cells and CD4^+^/CD8^+^ ratio, indicating that immune function of HC patients was improved after cinobufotalin injection-mediated therapy.

Safety is the top priority of the clinical treatment, and it is also a key factor for the development of cinobufotalin injection-mediated therapy. Our analysis showed no significant difference in most adverse events between the two groups, while the myelosuppression caused by TACE was obviously alleviated (*P*\<0.05), which proves the safety of cinobufotalin injection treatment for advanced HC.

Some factors may have influence on the therapeutic effects of cinobufotalin injection treatment. In our study, subgroup analysis was used for evaluating the impact of study design and sample size on therapeutic effects of cinobufotalin injection-mediated therapy. Our results found no difference between different study designs and sample sizes of studies in most indexes, except 0.5-year OS. However, currently, studies probing the impact of these factors on treatment effects of cinobufotalin injection adjuvant therapy are still insufficient, and these should be further researched and explored.

There are a few limitations in our study. First, all included researches were performed in different medical institutions in China, which may bring in regional bias and influence the clinical application of cinobufotalin injection-mediated therapy worldwide. In addition, different trials evaluated the treatment efficacy with different outcomes, resulting in a reduction in the size of the statistical sample, making it difficult to summarize the results at the same scale. Finally, the therapeutic effects of the combined therapy may be influenced by numerous variables such as chemotherapeutics types, tumor stage, tumor size, and patient's age. Due to the above limitations, future studies and generated data will be valuable to further verify the safety and efficacy of cinobufotalin injection-mediated therapy.

In summary, our study confirmed that TACE combined with cinobufotalin injection adjuvant therapy was an effective treatment for advanced HC patients. Intravenous infusion of cinobufotalin injection markedly enhanced the treatment efficacy of TACE for advanced HC. Moreover, cinobufotalin injection-mediated therapy can effectively improve the quality of life, immune function, and liver function of HC patients. Therefore, cinobufotalin injection-mediated therapy could be recommended as an adjuvant treatment method for end-stage HC.

Supplementary materials
=======================

###### 

Application sequence of and manufacturer of cinobufotalin injection

  Included studies                         Application sequence of cinobufotalin injection   Manufacturer
  ---------------------------------------- ------------------------------------------------- -----------------------------------------
  Chen et al (2017)[@b49-ott-11-8835]      After TACE                                        No description
  Cui (2008)[@b50-ott-11-8835]             Used simultaneously                               No description
  Deng and Duan (2015)[@b51-ott-11-8835]   Used simultaneously                               No description
  Fu et al (2010)[@b52-ott-11-8835]        Used simultaneously                               Anhui Golden Toad Biochemical Corp, Ltd
  He et al (2012)[@b53-ott-11-8835]        After TACE                                        No description
  Jia (2016)[@b54-ott-11-8835]             Used simultaneously                               Anhui Golden Toad Biochemical Corp, Ltd
  Ke et al (2011)[@b55-ott-11-8835]        Used simultaneously                               No description
  Kou and Xu (2011)[@b56-ott-11-8835]      After TACE                                        No description
  Li et al (2008)[@b57-ott-11-8835]        Used simultaneously                               No description
  Li (2014)[@b58-ott-11-8835]              Used simultaneously                               No description
  Liang et al (2008)[@b59-ott-11-8835]     After TACE                                        No description
  Liu et al (2009)[@b60-ott-11-8835]       Used simultaneously                               No description
  Liu et al (2010)[@b61-ott-11-8835]       Used simultaneously                               No description
  Mao (2013)[@b62-ott-11-8835]             Used simultaneously                               No description
  Shen (2009)[@b63-ott-11-8835]            After TACE                                        No description
  Shen and Tan (2015)[@b64-ott-11-8835]    After TACE                                        No description
  Song (2012)[@b65-ott-11-8835]            Used simultaneously                               Anhui Golden Toad Biochemical Corp, Ltd
  Su et al (2013)[@b66-ott-11-8835]        After TACE                                        Anhui Golden Toad Biochemical Corp, Ltd
  Sun et al (2002)[@b67-ott-11-8835]       After TACE                                        No description
  Wang (2014)[@b68-ott-11-8835]            Used simultaneously                               No description
  Xue et al (2010)[@b69-ott-11-8835]       Used simultaneously                               Anhui Golden Toad Biochemical Corp, Ltd
  Yan and Bai (2010)[@b70-ott-11-8835]     Used simultaneously                               No description
  Yang et al (2014)[@b71-ott-11-8835]      Used simultaneously                               Anhui Golden Toad Biochemical Corp, Ltd
  Yang et al (2006)[@b72-ott-11-8835]      Before TACE                                       Anhui Golden Toad Biochemical Corp, Ltd
  Yu (2013)[@b73-ott-11-8835]              Used simultaneously                               No description
  Zeng et al (2009)[@b74-ott-11-8835]      Before TACE                                       Anhui Golden Toad Biochemical Corp, Ltd
  Zhou et al (2006)[@b75-ott-11-8835]      After TACE                                        Anhui Golden Toad Biochemical Corp, Ltd

**Abbreviation:** TACE, transcatheter hepatic arterial chemoembolization.
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![Flow diagram of the selection process.](ott-11-8835Fig1){#f1-ott-11-8835}

![Risk of bias summary: review of authors' judgments about each risk of bias item for included studies.\
**Notes:** Each color represents a different level of bias: red, high risk; green, low risk; yellow, unclear risk.](ott-11-8835Fig2){#f2-ott-11-8835}

###### 

Forest plot of the comparison of 0.5-year (**A**), 1-year (**B**), 1.5-year (**C**), 2-year (**D**), and 3-year (**E**) OS between the experimental and control groups.

**Notes:** Control group, TACE alone group; experimental group, TACE+cinobufotalin injection combined therapy group. The fixed-effects meta-analysis model (Mantel-- Haenszel method) was used.

**Abbreviations:** OS, overall survival; TACE, transcatheter hepatic arterial chemoembolization.
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![Forest plot of the comparison of ORR (**A**) and DCR (**B**) between the experimental group and the control group.\
**Notes:** Control group, TACE alone group; experimental group, TACE+cinobufotalin injection combined therapy group. The fixed-effects meta-analysis model (Mantel-- Haenszel method) was used.\
**Abbreviations:** DCR, disease control rate; ORR, overall response rate; TACE, transcatheter hepatic arterial chemoembolization.](ott-11-8835Fig4){#f4-ott-11-8835}

![Forest plot of the comparison of QIR between the experimental group and the control group.\
**Notes:** Control group, TACE alone group; experimental group, TACE+cinobufotalin injection combined therapy group. The fixed-effects meta-analysis model (Mantel-- Haenszel method) was used.\
**Abbreviations:** M--H, Mantel--Haenszel; QIR, quality of life improved rate; TACE, transcatheter hepatic arterial chemoembolization.](ott-11-8835Fig5){#f5-ott-11-8835}

![Forest plot of the comparison of liver function indexes including TBIL, ALT, AST, and ALB between the experimental group and the control group.\
**Notes:** Control group, TACE alone group; experimental group, TACE+cinobufotalin injection combined therapy group. The random effects meta-analysis model (inverse variance method) was used.\
**Abbreviations:** ALB, serum albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; IV, inverse variance TACE, transcatheter hepatic arterial chemoembolization; TBIL, total bilirubin.](ott-11-8835Fig6){#f6-ott-11-8835}

![Forest plot of the comparison of immune function indexes including percentage of CD3^+^, CD4^+^, and NK cells and CD4^+^/CD8^+^ ratio between the experimental group and the control group.\
**Notes:** Control group, TACE alone group; experimental group, TACE+cinobufotalin injection combined therapy group. The random effects meta-analysis model (inverse variance method) was used.\
**Abbreviations:** NK, natural killer; TACE, transcatheter hepatic arterial chemoembolization.](ott-11-8835Fig7){#f7-ott-11-8835}

![Forest plot of the comparison of adverse effects including leukopenia, thrombocytopenia, diarrhea, nausea and vomiting, fever, hepatotoxicity, and myelosuppression between the experimental group and the control group.\
**Notes:** Control group, TACE alone group; experimental group, TACE+cinobufotalin injection combined therapy group. The random effects meta-analysis model (inverse variance method) was used.\
**Abbreviation:** TACE, transcatheter hepatic arterial chemoembolization.](ott-11-8835Fig8){#f8-ott-11-8835}

![Funnel plot of 0.5-year (**A**), 1-year (**B**), and 2-year (**C**) OS.\
**Abbreviation:** OS, overall survival; SE, standard error.](ott-11-8835Fig9){#f9-ott-11-8835}

![Funnel plot of ORR (**A**) and DCR (**B**).\
**Abbreviations:** DCR, disease control rate; ORR, overall response rate; SE, standard error.](ott-11-8835Fig10){#f10-ott-11-8835}

###### 

Clinical information from the eligible trials in the meta-analysis

  Included studies                         Nation   Stage             Patients (Con/exp)   Age (years)        Parameter types    
  ---------------------------------------- -------- ----------------- -------------------- ------------------ ------------------ -----------------------
  Chen et al (2017)[@b18-ott-11-8835]      China    Child-Pugh A--B   36/36                ND                 ND                 OS, ORR, DCR, QIR
  Cui (2008)[@b19-ott-11-8835]             China    Child-Pugh A--B   54/61                ND                 ND                 OS, ORR, DCR, QIR
  Deng and Duan (2015)[@b20-ott-11-8835]   China    ND                27/26                48.3±16.2 (mean)   48.7±16.1 (mean)   ORR, DCR, QIR, AE
  Fu et al (2010)[@b21-ott-11-8835]        China    KPS≥60            78/78                56 (median)        58 (median)        ORR, DCR, QIR, AE
  He et al (2012)[@b22-ott-11-8835]        China    Child-Pugh A--B   25/26                \>60 (20)          \>60 (19)          ORR, DCR, QIR, AE
  Jia (2016)[@b23-ott-11-8835]             China    Child-Pugh A--B   46/49                58.1±8.7 (mean)    58.4±8.3 (mean)    ORR, DCR
  Ke et al (2011)[@b24-ott-11-8835]        China    Child-Pugh A--B   40/38                57.1±11.8 (mean)   58.3±11.6 (mean)   OS, ORR, DCR
  Kou and Xu (2011)[@b25-ott-11-8835]      China    KPS.60            31/31                41 (mean)          40.5 (mean)        OS, ORR, DCR, QIR
  Li et al (2008)[@b26-ott-11-8835]        China    Child-Pugh A--B   46/50                ND                 ND                 OS, ORR, DCR, QIR
  Li (2014)[@b27-ott-11-8835]              China    ND                25/26                61.7±6.8 (mean)    57.4±6.2 (mean)    ORR, DCR
  Liang et al (2008)[@b28-ott-11-8835]     China    Child-Pugh A--C   48/48                ND                 ND                 OS, ORR, DCR, QIR, AE
  Liu et al (2009)[@b29-ott-11-8835]       China    ND                42/42                ND                 ND                 OS, ORR, DCR
  Liu et al (2010)[@b30-ott-11-8835]       China    Child-Pugh A--B   44/38                55.3±11.6 (mean)   54.2±10.3 (mean)   ORR, DCR, AE
  Mao (2013)[@b31-ott-11-8835]             China    I--III            27/27                48.3±8.9 (mean)    47.6±9.3 (mean)    OS, QIR
  Shen (2009)[@b32-ott-11-8835]            China    II--III           24/23                ND                 ND                 AE
  Shen and Tan (2015)[@b33-ott-11-8835]    China    Child-Pugh A--B   18/18                54.7 (mean)        57.5 (mean)        ORR, DCR
  Song (2012)[@b34-ott-11-8835]            China    I--II             20/20                49.8±6.4 (mean)    50.3±8.1 (mean)    OS, QIR
  Su et al (2013)[@b35-ott-11-8835]        China    II--III           30/33                52.7±7.9 (mean)    53.2±8.7 (mean)    ORR, DCR, QIR, AE
  Sun et al (2002)[@b36-ott-11-8835]       China    ND                118/118              ND                 ND                 OS, ORR
  Wang (2014)[@b37-ott-11-8835]            China    III--IV           35/36                ND                 ND                 ORR, DCR
  Xue et al (2010)[@b38-ott-11-8835]       China    KPS.60            30/32                45.5±10.7 (mean)   45.8±11.4 (mean)   OS, ORR, DCR, AE
  Yan and Bai (2010)[@b39-ott-11-8835]     China    II--IV            30/30                63.6 (mean)        65.4 (mean)        ORR, DCR
  Yang et al (2014)[@b40-ott-11-8835]      China    III--IV           45/45                62.3±7.2 (mean)    61.9±5.4 (mean)    ORR, DCR, AE
  Yang et al (2006)[@b41-ott-11-8835]      China    ND                40/40                44.3 (mean)        49.6 (mean)        OS, ORR, DCR
  Yu (2013)[@b42-ott-11-8835]              China    KPS.60            30/30                50.8 (mean)        49.7 (mean)        ORR, DCR
  Zeng et al (2009)[@b43-ott-11-8835]      China    Child-Pugh A--B   23/23                53.2±3.8 (mean)    52.4±3.7 (mean)    OS, ORR, DCR, QIR
  Zhou et al (2006)[@b44-ott-11-8835]      China    Child-Pugh A--C   22/21                ND                 ND                 OS, ORR, DCR

**Abbreviations:** AE, adverse event; Con, control group (TACE alone group); DCR, disease control rate; Exp, experimental group (TACE plus cinobufotalin injection adjuvant therapy); KPS, Karnofsky performance score; ND, not determined; ORR, overall response rate; OS, overall survival; QIR, quality of life improved rate; TACE, transcatheter hepatic arterial chemoembolization.

###### 

Information of TACE combined with cinobufotalin injection adjuvant therapy

  Included studies                         Therapeutic regimen                 Enrollment period (year.month)             Expected survival time (months)   
  ---------------------------------------- ----------------------------------- ------------------------------------------ --------------------------------- -----
  Chen et al (2017)[@b18-ott-11-8835]      TACE+cinobufotalin injection (IV)   TACE (oxaliplatin, THP)                    2014.7--2016.7                    \>3
  Cui (2008)[@b19-ott-11-8835]             TACE+cinobufotalin injection (IV)   TACE (5-Fu, ADR, mitomycin, HCPT)          2000.6--2007.6                    ND
  Deng and Duan (2015)[@b20-ott-11-8835]   TACE+cinobufotalin injection (IV)   TACE (DDP, THP)                            2011.1--2013.2                    ND
  Fu et al (2010)[@b21-ott-11-8835]        TACE+cinobufotalin injection (IV)   TACE (DDP, 5-Fu, mitomycin)                2006.6--2009.10                   \>4
  He et al (2012)[@b22-ott-11-8835]        TACE+cinobufotalin injection (IV)   TACE (5-Fu, oxaliplatin, THP)              2007.3--2010.8                    \>3
  Jia (2016)[@b23-ott-11-8835]             TACE+cinobufotalin injection (IV)   TACE (DDP, 5-Fu, ADR)                      2010.1--2012.6                    \>3
  Ke et al (2011)[@b24-ott-11-8835]        TACE+cinobufotalin injection (IV)   TACE (DDP, 5-Fu, E-ADM)                    2006.2--2008.3                    \>3
  Kou and Xu (2011)[@b25-ott-11-8835]      TACE+cinobufotalin injection (IV)   TACE (DDP, 5-Fu, ADR, HCPT)                2003.5--2008.5                    \>3
  Li et al (2008)[@b26-ott-11-8835]        TACE+cinobufotalin injection (IV)   TACE (5-Fu, ADR, mitomycin, HCPT)          2001--2005                        ND
  Li (2014)[@b27-ott-11-8835]              TACE+cinobufotalin injection (IV)   TACE (5-Fu, ADR, oxaliplatin, mitomycin)   2012.8--2013.8                    ND
  Liang et al (2008)[@b28-ott-11-8835]     TACE+cinobufotalin injection (IV)   TACE (DDP, 5-Fu, ADR)                      2004.2--2006.2                    ND
  Liu et al (2009)[@b29-ott-11-8835]       TACE+cinobufotalin injection (IV)   TACE (DDP, 5-Fu, E-ADM)                    2002.6--2006.6                    ND
  Liu et al (2010)[@b30-ott-11-8835]       TACE+cinobufotalin injection (IV)   TACE (DDP, THP, mitomycin)                 2005.6--2008.1                    \>3
  Mao (2013)[@b31-ott-11-8835]             TACE+cinobufotalin injection (IV)   TACE (5-Fu, ADR, mitomycin)                2007.6--2010.6                    ND
  Shen (2009)[@b32-ott-11-8835]            TACE+cinobufotalin injection (IV)   TACE (DDP, 5-Fu, mitomycin)                2004--2007                        \>2
  Shen and Tan (2015)[@b33-ott-11-8835]    TACE+cinobufotalin injection (IV)   TACE (5-Fu, lobaplatin, THP)               2013.3--2014.12                   ND
  Song (2012)[@b34-ott-11-8835]            TACE+cinobufotalin injection (IV)   TACE (5-Fu, ADR, mitomycin)                2007.1--2010.12                   \>3
  Su et al (2013)[@b35-ott-11-8835]        TACE+cinobufotalin injection (IV)   TACE (5-Fu, ADR, mitomycin, HCPT)          2008.6--2012.6                    \>2
  Sun et al (2002)[@b36-ott-11-8835]       TACE+cinobufotalin injection (IV)   TACE (carboplatin, mitomycin, E-ADM)       1994.6--2000.6                    ND
  Wang (2014)[@b37-ott-11-8835]            TACE+cinobufotalin injection (IV)   TACE (DDP, 5-Fu, ADR)                      ND                                ND
  Xue et al (2010)[@b38-ott-11-8835]       TACE+cinobufotalin injection (IV)   TACE (DDP, 5-Fu, ADR)                      2003.1--2005.10                   \>3
  Yan and Bai (2010)[@b39-ott-11-8835]     TACE+cinobufotalin injection (IV)   TACE (DDP, 5-Fu, ADR, mitomycin, HCPT)     2004.12--2010.1                   ND
  Yang et al (2014)[@b40-ott-11-8835]      TACE+cinobufotalin injection (IV)   TACE (DDP, 5-Fu, ADMh, mitomycin)          2010.6--2013.6                    ≥3
  Yang et al (2006)[@b41-ott-11-8835]      TACE+cinobufotalin injection (IV)   TACE (DDP, 5-Fu, mitomycin, gemcitabine)   1996.7--2002.3                    \>3
  Yu (2013)[@b42-ott-11-8835]              TACE+cinobufotalin injection (IV)   TACE (DDP, 5-Fu, ADR, mitomycin)           2003.2--2011.5                    ND
  Zeng et al (2009)[@b43-ott-11-8835]      TACE+cinobufotalin injection (IV)   TACE (DDP, 5-Fu, THP)                      2002.2--2006.5                    ND
  Zhou et al (2006)[@b44-ott-11-8835]      TACE+cinobufotalin injection (IV)   TACE (DDP, 5-Fu, mitomycin)                2002.12--2005.12                  \>2

**Abbreviations:** ADMh, doxorubicin hydrochloride; ADR, adriamycin; Con, control group (TACE alone group); DDP, cisplatin; E-ADM, pharmorubicin; Exp, experimental group (TACE plus cinobufotalin injection adjuvant therapy); 5-Fu, 5-fluorouracil; HCPT, hydroxycamptothecin; IV, intravenous; ND, not determined; TACE, transcatheter hepatic arterial chemoembolization; THP, pirarubicin.

###### 

Comparison of CR, PR, SD, PD, ORR, and DCR between the TACE and TACE+cinobufotalin injection groups

  Parameter   TACE+cinobufotalin injection group (n)   TACE group (n)   Analysis method   Heterogeneity   OR     95% CI   *P*-value    
  ----------- ---------------------------------------- ---------------- ----------------- --------------- ------ -------- ------------ -----------
  CR          816                                      802              Fixed             0               0.93   1.73     1.04--2.87   0.03
  PR          816                                      802              Fixed             0               0.94   1.61     1.31--1.97   \<0.00001
  SD          856                                      842              Fixed             0               0.86   0.88     0.72--1.09   0.25
  PD          856                                      842              Fixed             0               0.99   0.46     0.35--0.59   \<0.00001
  ORR         974                                      960              Fixed             0               0.66   1.86     1.54--2.24   \<0.00001
  DCR         856                                      842              Fixed             0               0.92   2.05     1.59--2.64   \<0.00001

**Abbreviations:** CR, complete response; DCR, disease control rate; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease; TACE, transcatheter hepatic arterial chemoembolization.

###### 

Publication bias on OS, CR, PR, SD, PD, ORR, DCR, and QIR

  Publication bias   0.5-year OS   1-year OS   2-year OS   CR      PR      SD      PD      ORR     DCR     QIR
  ------------------ ------------- ----------- ----------- ------- ------- ------- ------- ------- ------- -------
  Begg               0.152         0.077       0.755       0.436   0.195   0.492   0.413   0.747   0.444   0.300
  Egger              0.110         0.070       0.564       0.151   0.191   0.383   0.134   0.821   0.207   0.335

**Abbreviations:** CR, complete response; DCR, disease control rate; ORR, overall response rate; OS, overall survival; PD, progressive disease; PR, partial response; QIR, quality of life improved rate; SD, stable disease.

###### 

Subgroup analyses of ORR and DCR between the Exp and Con groups

  Parameter                    Factors at study level   Exp group (n)   Con group (n)   Analysis method   Heterogeneity   OR     95% CI       *P*-value
  ---------------------------- ------------------------ --------------- --------------- ----------------- --------------- ------ ------------ -----------
  0.5-year OS                  **Study sample size**                                                                                          
  ≥80                          199                      188             Fixed           0                 0.77            1.09   0.67--1.79   0.73
  \<80                         176                      176             Fixed           0                 0.89            1.86   1.08--3.19   0.02
  **Type of control trials**                                                                                                                  
  RCT                          314                      310             Fixed           0                 0.90            1.55   1.03--2.32   0.03
  Total                        375                      364             Fixed           0                 0.86            1.40   0.97--2.01   0.07
  1-year OS                    **Study sample size**                                                                                          
  ≥80                          359                      348             Fixed           4                 0.39            3.41   2.47--4.71   \<0.00001
  \<80                         207                      207             Fixed           0                 0.95            2.07   1.35--3.17   0.0008
  **Type of control trials**                                                                                                                  
  RCT                          505                      501             Fixed           0                 0.53            2.85   2.17--3.75   \<0.00001
  Total                        566                      555             Fixed           0                 0.61            2.84   2.20--3.67   \<0.00001
  2-year OS                    **Study sample size**                                                                                          
  ≥80                          311                      300             Fixed           0                 0.80            3.74   2.59--5.38   \<0.00001
  \<80                         154                      153             Fixed           0                 0.73            2.33   1.42--3.83   0.0009
  **Type of control trials**                                                                                                                  
  RCT                          404                      399             Fixed           0                 0.66            3.21   2.35--4.39   \<0.00001
  Total                        465                      453             Fixed           0                 0.74            3.17   2.36--4.25   \<0.00001
  ORR                          **Study sample size**                                                                                          
  ≥80                          569                      561             Fixed           0                 0.49            1.96   1.53--2.50   \<0.00001
  \<80                         405                      399             Fixed           0                 0.62            1.74   1.30--2.32   0.0002
  **Type of control trials**                                                                                                                  
  RCT                          883                      876             Fixed           0                 0.61            1.82   1.49--2.21   \<0.00001
  Total                        974                      960             Fixed           0                 0.66            1.86   1.54--2.24   \<0.00001
  DCR                          **Study sample size**                                                                                          
  ≥80                          451                      443             Fixed           0                 0.71            1.93   1.35--2.75   0.0003
  \<80                         405                      399             Fixed           0                 0.85            2.18   1.52--3.14   \<0.0001
  **Type of control trials**                                                                                                                  
  RCT                          765                      758             Fixed           0                 0.86            2.04   1.55--2.68   \<0.00001
  Total                        856                      842             Fixed           0                 0.92            2.05   1.59--2.64   \<0.00001
  QIR                          **Study sample size**                                                                                          
  ≥80                          237                      226             Fixed           0                 0.57            4.04   2.50--6.52   \<0.00001
  \<80                         242                      238             Fixed           0                 0.99            3.05   2.02--4.63   \<0.00001
  **Type of control trials**                                                                                                                  
  RCT                          418                      410             Fixed           0                 0.99            3.31   2.40--4.56   \<0.00001
  Total                        479                      464             Fixed           0                 0.99            3.45   2.52--4.72   \<0.00001

**Abbreviations:** Con, control group (TACE alone group); DCR, disease control rate; Exp, experimental group (TACE plus cinobufotalin injection adjuvant therapy); ORR, overall response rate; OS, overall survival; QIR, quality of life improved rate; RCT, randomized controlled trial.
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